Price Alert

Exact Sciences Corporatio... (EXAS)

NASDAQ: EXAS · Real-Time Price · USD

44.99

0.08 (0.18%)

At close: Aug 14, 2025, 3:59 PM

45.50

1.13%

Pre-market: Aug 15, 2025, 04:00 AM EDT

0.18% (1D)

Bid	45.11
Market Cap	8.52B
Revenue (ttm)	2.94B
Net Income (ttm)	-1.01B
EPS (ttm)	-5.45
PE Ratio (ttm)	-8.26
Forward PE	117.04
Analyst	Buy

Ask	46
Volume	3,546,975
Avg. Volume (20D)	3,200,848
Open	44.74
Previous Close	44.91
Day's Range	43.66 - 45.08
52-Week Range	38.81 - 72.83
Beta	0.93

About EXAS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EXAS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EXAS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Exact Sciences has released their quartely earnings on Aug 6, 2025:

Revenue of $811.09M exceeds estimates by $3.95M, with 15.99% YoY growth.

EPS of -0.01 misses estimates by -0.03, with 88.89% YoY growth.

Next Earnings Release

Exact Sciences Corporation is scheduled to release its earnings on Nov 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-7.99%

Exact Sciences shares are trading lower following ... Unlock content with Pro Subscription

1 week ago

-0.95%

Exact Sciences shares are trading lower following the release of its Q2 financial results.

News

3 days ago · zacks.com

EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up

Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.

3 days ago · fool.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value investor. The Ark Invest co-founder, CEO, and chief investment officer is often a...

3 days ago · zacks.com

Here's Why Exact Sciences (EXAS) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

4 days ago · benzinga.com

Top 3 Health Care Stocks That Are Preparing To Pump This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

1 week ago · benzinga.com

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. EXAS on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

1 week ago · zacks.com

Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 week ago · seekingalpha.com

Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript

Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Derek Leckow - Vice President of Inves...

1 week ago · zacks.com

Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates

Exact Sciences (EXAS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.09 per share a year ago.

1 week ago · fool.com

Exact Sciences (EXAS) Q2 Revenue Up 16%

1 week ago · businesswire.com

Exact Sciences Announces Second Quarter 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for...

Load More News